^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Glioblastoma
    Drug:paxalisib (GDC-0084) (mTOR inhibitor, PI3K inhibitor, AKT inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Nasdaq
    Title:

    US FDA AWARDS FAST TRACK DESIGNATION (FTD) TO PAXALISIB FOR GLIOBLASTOMA

    Published date:
    08/20/2020
    Excerpt:
    ...Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that the United States Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to Kazia’s paxalisib (formerly GDC-0084) for the treatment of glioblastoma, the most common and most aggressive form of primary brain cancer.